相关实验视频

Updated: Jun 15, 2025

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

肝素结合蛋白在新生儿败血症中的潜在作用:研究进展

Xiyang Chen¹, Haiting Li¹, Jie Li¹

¹Department of Neonatology and Neonatal Intensive Care Unit, Wenling Maternal and Child Health Care Hospital, Wenling, Zhejiang, China.

Frontiers in cellular and infection microbiology

|August 28, 2024

概括

肝素结合蛋白 (HBP) 是一个有前途的生物标志物,用于早期预测和评估新生儿败血症的严重程度. 需要进一步的研究来澄清其在诊断和治疗中的全部临床效用.

科学领域:

生物化学生物化学
新生儿医学新生儿医学
免疫学免疫学免疫学

背景情况:

新生儿败血症是全球新生儿发病和死亡的主要原因.
新生儿败血症的早期和准确诊断仍然是一个临床挑战.
肝素结合蛋白 (HBP) 是在感染期间由中性粒细胞释放的.

研究的目的:

审查当前对新生儿败血症中肝素结合蛋白 (HBP) 的理解.
探索HBP作为诊断和预后生物标志物的潜力.
讨论HBP在新生儿护理中的未来临床应用.

主要方法:

对HBP和新生儿败血症研究的文献综述.
分析HBP在炎症反应和感染中的作用.
评估HBP与临床结果和死亡率的相关性.

主要成果:

乙型肝炎水平随着感染而动态变化,与死亡率有关.
HBP显示出早期诊断和新生儿败血症严重程度分层的潜力.
乙型肝炎可能有助于指导抗生素治疗决策.

结论:

乙型肝炎是新生儿败血症诊断和预后的一个有前途的生物标志物.
需要进一步进行广泛的研究,以确定HBP的确切临床效用.
乙型肝炎可能会改善新生儿败血症的管理和抗生素管理.

关键词:

生物标志物生物标志物早期诊断早期诊断早期诊断氨酸结合蛋白质 - 氨酸结合蛋白质新生儿败血症新生儿败血症治疗性干预是一种治疗性干预.

更多相关视频

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity

Published on: February 17, 2017

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis

Published on: January 27, 2019

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...